Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 19:6:2329048X19831486.
doi: 10.1177/2329048X19831486. eCollection 2019.

Glycine Transporter 1 Encephalopathy From Biochemical Pathway to Clinical Disease: Review

Rayan Alfallaj  1 , Majid Alfadhel  1   2
Affiliations
Review

Glycine Transporter 1 Encephalopathy From Biochemical Pathway to Clinical Disease: Review

Rayan Alfallaj et al. Child Neurol Open. .

Abstract

Glycine transporter 1 encephalopathy (OMIM# 617301; glycine encephalopathy with normal serum glycine, GLYT1 transporter dysfunction, and nonketotic hyperglycinemia) is caused by mutations in the SLC6A9 gene. To date, 6 cases have been reported in the literature, characterized as having neonatal onset, respiratory failure that required mechanical ventilation, severe hypotonia at birth that progressed to limb hypertonicity, and startle-like responses provoked by sudden loud noises and tactile stimulation. Additional characteristics included dysmorphic features, musculoskeletal abnormalities, and abnormal antenatal findings. Initial diagnosis include elevated levels of glycine in cerebrospinal fluid and an elevated cerebrospinal fluid to plasma glycine ratio. Abnormal magnetic resonance imaging findings included white matter abnormalities, thin corpus callosum, dilatation of the lateral and third ventricles, caudate atrophy, and tiny cysts. Patients reported so far showed normal electroencephalogram results. Treatment was supportive and appeared severe as 50% of the patients died between 2 days and 7 months of age, while surviving children had global developmental delay. In this report, we reviewed the published cases having glycine transporter 1 encephalopathy and retrospectively characterizing the disease phenotypes, affected biochemical pathways, neuroradiological abnormalities, diagnosis, genetic issues, and treatment; additionally, key discussion points are also presented.

Keywords: GLYT1 encephalopathy; GLYT1 transporter dysfunction; SLC6A9 gene; autosomal recessive nonketotic hyperglycinemia.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Applegarth DA, Toone JR. Glycine encephalopathy (nonketotic hyperglycinemia): comments and speculations. Am J Med Genet A. 2006;140(2):186–188. - PubMed
    1. Alfadhel M, Nashabat M, Qahtani HA, et al. Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016;135(11):1263–1268. - PMC - PubMed
    1. Kurolap A, Armbruster A, Hershkovitz T, et al. Loss of glycine transporter 1 causes a subtype of glycine encephalopathy with arthrogryposis and mildly elevated cerebrospinal fluid glycine. Am J Hum Genet. 2016;99(5):1172–1180. - PMC - PubMed
    1. Kurolap A, Hershkovitz T, Baris HN. GLYT1 Encephalopathy In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews(R). Seattle, WA: 1993. - PubMed
    1. Eulenburg V, Armsen W, Betz H, Gomeza J. Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci. 2005;30(6):325–333. - PubMed

LinkOut - more resources